Be A Freedom Fighter · Bill Library
HR 10857 — To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Freedom score: -3 (scale −10 to +10)
- Individual rights: +1
- Property rights: -1
- Economic freedom: +1
- Privacy & due process: -2
- Government power: -2
Sponsor: Rep. Auchincloss, Jake [D-MA-4] · Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (2026-10-22)
Full text on GovInfo (introduced version) · Congress.gov · ← Bill Library index
Findings — 114 highlighted provisions
Each item below is one provision documented in the findings file. The same provision is highlighted in the full text underneath, with its section citation and criterion. Everything else on this page is plain, unreviewed bill text.
- Sec. 101–107 — 201–205, 301–307, 401–403, and 501 See in text ↓
- Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated See in text ↓
- Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment See in text ↓
- Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine See in text ↓
- Sec. 107(b)–(c) · Individual Rights — Requires HHS within one year to make rules for fair compensation of clinical-trial participants and participating sites, taking account of research risks, burdens and undue influence. Affected: participants, investigators and sponsors. Mechanism: future rules and existing research oversight See in text ↓
- Sec. 106(b)(2) · Property Rights — Requires IRB-disclosure rules to preserve confidential commercial information and trade secrets while publishing decision summaries. Affected: sponsors and research institutions. Mechanism: HHS/FDA/NIH rulemaking and existing confidentiality protections See in text ↓
- Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions See in text ↓
- Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines See in text ↓
- Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration See in text ↓
- Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority See in text ↓
- Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting See in text ↓
- Sec. 101(a), new §499B(l); Sec. 101(b)(1)–(2) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for the initiative, and revises FDA Innovation Account transfers to $20m/$60m/$70m/$75m/$70m in FY2027–2031 and related appropriation authorization. Distinguish authorized appropriations from mandated transfers. Affected: federal programs and award recipients See in text ↓
- Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions See in text ↓
- Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors See in text ↓
- Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting See in text ↓
- Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation See in text ↓
- Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight See in text ↓
- Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process See in text ↓
- Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation See in text ↓
- Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance See in text ↓
- Sec. 106(c) · Economic Freedom — Expands FDA bioresearch monitoring through user-fee performance commitments. Mechanism: existing FDA inspection/oversight See in text ↓
- Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance See in text ↓
- Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law See in text ↓
- Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards See in text ↓
- Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes See in text ↓
- Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty See in text ↓
- Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight See in text ↓
- Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking See in text ↓
- Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties See in text ↓
- Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers See in text ↓
- Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication See in text ↓
- Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA See in text ↓
- Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope See in text ↓
- Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules See in text ↓
- Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation See in text ↓
- Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process See in text ↓
- Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer See in text ↓
- Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval See in text ↓
- Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender See in text ↓
- Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules See in text ↓
- Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules See in text ↓
- Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty See in text ↓
- Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval See in text ↓
- Sec. 203(b), new FDCA §704(i)(1)–(2) · Economic Freedom — Requires inspected clinical establishments to pre-certify GCP compliance; requires verification for covered biotechnology companies of concern and authorizes inspection-cost fees. Affected: site owners/operators/agents. Mechanism: FDA inspection, fees and approval decisions See in text ↓
- Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data See in text ↓
- Sec. 203(d) · Economic Freedom — Requires FDA within 18 months to clarify consequences for delaying/denying inspections. Mechanism: guidance and existing inspection law See in text ↓
- Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review See in text ↓
- Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards See in text ↓
- Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations See in text ↓
- Sec. 201(c)(1)(B) · Privacy and Due Process — Includes data-security and proprietary safeguards in the new-methodology validation policy. Mechanism: FDA guidance See in text ↓
- Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls See in text ↓
- Sec. 203(b), new FDCA §704(i)(1)–(2) · Privacy and Due Process — Imposes pre-certification and federal verification/inspection of specified clinical sites, with inspection cost fees. Mechanism: FDA inspection authority See in text ↓
- Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA See in text ↓
- Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions See in text ↓
- Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties See in text ↓
- Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines See in text ↓
- Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers See in text ↓
- Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers See in text ↓
- Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions See in text ↓
- Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight See in text ↓
- Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure See in text ↓
- Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified See in text ↓
- Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope See in text ↓
- Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval See in text ↓
- Sec. 301(b) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for process improvements, available until expended; not automatically appropriated See in text ↓
- Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law See in text ↓
- Sec. 302(b), amended FDCA §803(b)(3) · Economic Freedom — Requires bioresearch monitoring to seek reciprocal inspection reliance, reduced duplicate U.S. inspections and risk-based oversight. Mechanism: FDA regulatory collaboration See in text ↓
- Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval See in text ↓
- Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law See in text ↓
- Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review See in text ↓
- Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure See in text ↓
- Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review See in text ↓
- Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law See in text ↓
- Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements See in text ↓
- Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty See in text ↓
- Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031 See in text ↓
- Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination See in text ↓
- Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps See in text ↓
- Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance See in text ↓
- Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications See in text ↓
- Sec. 306(1)–(5) · Government Power — Requires GAO report within three years See in text ↓
- Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties See in text ↓
- Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section See in text ↓
- Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law See in text ↓
- Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration See in text ↓
- Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation See in text ↓
- Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process See in text ↓
- Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers See in text ↓
- Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections See in text ↓
- Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures See in text ↓
- Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation See in text ↓
- Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031 See in text ↓
- Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers See in text ↓
- Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment See in text ↓
- Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law See in text ↓
- Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards See in text ↓
- Sec. 501(a), new §404P(i) · Economic Freedom — Authorizes $500 million for FY2027 and each subsequent fiscal year, available until expended; no statutory end date. This is an authorization, not an automatic appropriation See in text ↓
- Sec. 501(b) · Economic Freedom — Requires NIH within 180 days to submit a five-fiscal-year scientific, infrastructure, partnership-financing and budget roadmap. Mechanism: congressional oversight See in text ↓
- Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law See in text ↓
- Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight See in text ↓
- Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law See in text ↓
- Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation See in text ↓
- Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy See in text ↓
- Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator See in text ↓
- Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board See in text ↓
- Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives See in text ↓
- Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance See in text ↓
- Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset See in text ↓
- Sec. 501(b) · Government Power — Requires a five-year implementation and financing roadmap within 180 days See in text ↓
- Sec. 203(c)(2) · Government Power — and may charge inspection fees See in text ↓
- Sec. 203(b) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization See in text ↓
- Sec. 501(a), Sec. 404P(i) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization See in text ↓
- Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration See in text ↓
- Sec. 501(a), Sec. 404P(d)(5)–(10) · Government Power — notwithstanding explicit consent safeguards See in text ↓
- Sec. 404P(g) · Government Power — Consequently Direction changes from −2 to −3, and Impact remains 18. This is a rubric judgment subject to human review, not a statement that the biobank compels public participation Provision location not found in introduced text — see finding.
Full text (introduced version)
359 of 379 text blocks highlighted. Source: GovInfo, fetched cached.
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
SEC. 101. CURES IN CARE INITIATIVE.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority
Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting
Sec. 101(a), new §499B(l); Sec. 101(b)(1)–(2) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for the initiative, and revises FDA Innovation Account transfers to $20m/$60m/$70m/$75m/$70m in FY2027–2031 and related appropriation authorization. Distinguish authorized appropriations from mandated transfers. Affected: federal programs and award recipients
Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 101(a), new §499B(c)(6)(B)–(C), (i)(1)–(3) · Privacy and Due Process — Requires coordination on electronic consent, interoperable clinical/real-world data, confidentiality protections, monitoring and central IRB reliance. Mechanism: program standards and FDA guidance
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(c)(1)–(8) · Economic Freedom — Directs the FDA Center to select priority disease areas, build networks, favor under-resourced sites, certify sites and award grants, contracts, cooperative agreements and other transactions. Affected: clinical sites, sponsors and contractors. Mechanism: federal award and certification conditions
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(d)(1)–(2), (e)(1)–(3) · Economic Freedom — Requires at least three networks within one year and an expansion plan within three years with specified access, cost, accrual, reporting and performance goals, followed by public posting. Mechanism: federal implementation/reporting duties, not direct provider fines
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new PHSA §499B(c)(3)–(5), (e)(1)(A), (g)(1)–(4) · Individual Rights — Prioritizes less-resourced care sites, requires each network to cover at least one high-burden chronic disease and related rare-disease group, designates a central IRB, and sets patient/site-access implementation goals. Affected: participating patients and clinical sites. Mechanism: FDA program/network and award administration, not compelled patient enrollment
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(f)(1)–(2), (g)(1)–(5) · Economic Freedom — Mandates consultation with CMS, ARPA-H, HRSA, health IT, FDA biologics and stakeholders; authorizes VA/DoD consultation; requires online technical assistance, prioritizing less-resourced sites, and permits training contracts. Mechanism: federal program administration
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(h)–(i) · Economic Freedom — Requires FDA external engagement and guidance within 18 months on decentralized trials, central IRBs, electronic consent, monitoring and real-world evidence. Mechanism: guidance and existing FDA authority
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(j)(1)–(2) · Economic Freedom — Requires annual public/congressional progress reports and evaluations after three and five years. Mechanism: agency reporting
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101(a), new §499B(l); Sec. 101(b)(1)–(2) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for the initiative, and revises FDA Innovation Account transfers to $20m/$60m/$70m/$75m/$70m in FY2027–2031 and related appropriation authorization. Distinguish authorized appropriations from mandated transfers. Affected: federal programs and award recipients
Sec. 101(a), new §499B(c)–(l); Sec. 101(b) · Government Power — Grants FDA network designation, certification, guidance, awards, reporting and training powers; sets deadlines and substantial FY2027–2031 funding authorities and account transfers
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 101(a), new §499B(a)–(b) · Government Power — Establishes an FDA Center for Clinical Trial Innovation and a Cures in Care Initiative, with HHS, FDA and NIH coordination. Mechanism: statutory administrative duties
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
SEC. 102. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 102, new §499C(a)(1)–(2) · Economic Freedom — Requires grants or other agreements with at least three networks within a year, tied to measurable evidence improvements within three years of first appropriation and expansion beyond initial networks. Mechanism: award conditions
Sec. 102, new §499C(b)(1)–(11) · Economic Freedom — Permits award conditions on data standards, infrastructure, virtual participation, adverse-event and outcome data, phase 2–4 and postmarket research, under-resourced patients/sites, biotech companies, commercial developer collaboration, and sustainability/nonfederal support plans. Mechanism: grant/contract compliance; not universal mandates on all trial sponsors
Sec. 102, new §499C(c)(1)–(2), (d)(1)–(2) · Economic Freedom — Limits awards to five years, permits extensions up to three years upon qualifying contribution, and requires evaluations and annual public posting after year three. Mechanism: award term and reporting
Sec. 102, new §499C(e)(1)–(4) · Economic Freedom — Authorizes such sums as necessary FY2027–2031, permits common-fund reservations and qualifying intradepartmental transfers, and requires budget specification. Mechanism: fiscal/award administration, not automatic appropriation
Sec. 102, new §499C(b)(1), new §499C(b)(4) · Privacy and Due Process — Permits award conditions requiring common data standards and plans to collect/share treatment, covariate, outcome and adverse-event information. Affected: award recipients and trial participants. Mechanism: federal awards and applicable privacy law
Sec. 102, new §499C(a)–(e) · Government Power — Creates the lead-network grant/contract program with performance evaluations, maximum award durations, fiscal transfers and annual publication
SEC. 103. CURES IN CARE INITIATIVE COLLABORATIVE.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 103, new §499D(a)–(b) · Economic Freedom — Establishes a public-private Collaborative to develop methodologies, remove trial barriers and support networks; assigns evaluation, technology integration, recruitment and shared-services duties. Affected: partners and clinical sites. Mechanism: agreement and program oversight
Sec. 103, new §499D(c) · Economic Freedom — Exempts this Collaborative from the Federal Advisory Committee Act. Mechanism: statutory exception to the usual federal advisory-committee process
Sec. 103, new §499D(a)–(c) · Government Power — Creates a public-private Collaborative and exempts it from FACA
SEC. 104. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED ACTIVITIES.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 104, new §499E(1)–(6) · Economic Freedom — Incorporates regulatory definitions of clinical investigations and innovative designs; defines disease areas, networks, less-resourced sites and point-of-care trials, limiting who can qualify for related program activities. Mechanism: eligibility interpretation
Sec. 104, new §499E(1)–(6) · Government Power — Establishes binding definitions for program eligibility and scope
SEC. 105. DATA STANDARDS WITH RESPECT TO DATA SHARING.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(a)–(d) · Privacy and Due Process — Requires CMS, FDA and the health-IT coordinator within 18 months to list named interoperability and clinical-study standards, update at least every three years, and publish regulatory-translation specifications within 12 months. Mechanism: federal technical standards
Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes
Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(e) · Privacy and Due Process — Permits CMS linkage/tokenization capabilities for trial data only in compliance with HIPAA, the Privacy Act and 42 CFR part 2. Affected: patient data holders and participants. Mechanism: incorporated privacy statutes
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty
Sec. 105(a)–(f); Sec. 106(a)–(c); Sec. 107(a)–(c) · Government Power — Assigns interagency data standards, FDA IRB rulemaking/monitoring, and CMS trial coverage and participant-payment rules
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 105(f) · Privacy and Due Process — Directs federal assessment of real-world data and AI/digital tools for product-efficacy, label-expansion and regulatory decisionmaking. Mechanism: agency assessment; no new individual disclosure penalty
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
SEC. 106. CLINICAL TRIAL OVERSIGHT MODERNIZATION.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance
Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance
Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance
Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance
Sec. 106(a)(1)–(3) · Privacy and Due Process — Centralizes IRB review with limited alternatives; changes review procedure rather than eliminating human-subject protections. Mechanism: FDA rulemaking and IRB oversight
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(a)(1)–(4) · Economic Freedom — Requires one IRB for covered multi-institutional clinical investigations, allowing alternatives when the sponsor demonstrates necessity; FDA must make implementing rules within one year. Affected: sponsors and IRBs. Mechanism: existing human-subjects/FDA compliance
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(b)(2) · Property Rights — Requires IRB-disclosure rules to preserve confidential commercial information and trade secrets while publishing decision summaries. Affected: sponsors and research institutions. Mechanism: HHS/FDA/NIH rulemaking and existing confidentiality protections
Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(b)(2) · Property Rights — Requires IRB-disclosure rules to preserve confidential commercial information and trade secrets while publishing decision summaries. Affected: sponsors and research institutions. Mechanism: HHS/FDA/NIH rulemaking and existing confidentiality protections
Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(b)(1)–(3) · Privacy and Due Process — Requires rules within one year to publish IRB deliberation summaries and decision bases, while protecting health information, trade secrets and confidential business information, preferably through ClinicalTrials.gov. Mechanism: agency rulemaking
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 106(c) · Economic Freedom — Expands FDA bioresearch monitoring through user-fee performance commitments. Mechanism: existing FDA inspection/oversight
SEC. 107. UPDATES TO PATIENT COSTS AND PAYMENT FOR PARTICIPATION IN CLINICAL TRIALS.
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 107(a)(1)(A)–(B), (a)(2) · Individual Rights — Requires CMS within 18 months to clarify Medicare routine-cost coverage for qualifying point-of-care trials, including digital/remote care, align quality data standards, and address use of such evidence in national coverage decisions. Affected: Medicare beneficiaries, providers, sponsors. Mechanism: existing Medicare coverage determinations; no standalone fine
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 107(b)–(c) · Individual Rights — Requires HHS within one year to make rules for fair compensation of clinical-trial participants and participating sites, taking account of research risks, burdens and undue influence. Affected: participants, investigators and sponsors. Mechanism: future rules and existing research oversight
Sec. 101–107 — 201–205, 301–307, 401–403, and 501
Sec. 107(b)–(c) · Individual Rights — Requires HHS within one year to make rules for fair compensation of clinical-trial participants and participating sites, taking account of research risks, burdens and undue influence. Affected: participants, investigators and sponsors. Mechanism: future rules and existing research oversight
SEC. 201. MODERNIZED EVIDENCE GENERATION THROUGH NEW APPROACH METHODOLOGIES.
Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(a)(1)–(2) · Economic Freedom — Requires FDA guidance/evidence frameworks within two years on in-vitro, in-silico and other new methodologies for preclinical studies and IND submissions. Mechanism: future guidance and existing drug approval
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(c)(1)(B) · Privacy and Due Process — Includes data-security and proprietary safeguards in the new-methodology validation policy. Mechanism: FDA guidance
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(2), (c)(1)(B)–(C) · Property Rights — Requires consideration of intellectual-property/proprietary protections as incentives for sponsors to share preclinical-methodology data. Affected: drug sponsors and technology developers. Mechanism: future FDA validation policy; no immediate compulsory patent transfer
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(c)(1)(B) · Privacy and Due Process — Includes data-security and proprietary safeguards in the new-methodology validation policy. Mechanism: FDA guidance
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
Sec. 201(b)(1)–(3), (c)(1)–(4) · Economic Freedom — Requires stakeholder workshops and FDA/NIH/ARPA-H data-sharing/validation policies, including security, proprietary protections, possible grant/contract financing and international coordination. Mechanism: agency policies, not immediate mandatory data surrender
Sec. 201(a)–(c) · Government Power — Expands FDA evidence-framework, workshops and methodology-validation duties
SEC. 202. MODERNIZED PHASE 1 CLINICAL TRIAL OVERSIGHT.
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a), (b)(1)–(5) · Individual Rights — Establishes an expedited review procedure and third-party pilot for lower-risk phase 1 trials, including qualified IRBs/third parties, FDA safeguards and specialized gene/cell-therapy support. Affected: sponsors and potential volunteer patients. Mechanism: FDA trial authorization/oversight, not compulsory participation
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(b)(2)–(5) · Privacy and Due Process — Provides qualification and safety review for delegated third-party trial assessments; high-risk categories are not automatically eligible for expedited review. Mechanism: FDA/IRB controls
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(a)–(b) · Economic Freedom — Requires an expedited lower-risk phase 1 review procedure and third-party pilot; qualification turns on review competence, IRB status and other FDA requirements. Mechanism: existing IND/IRB rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(c)(1)–(3), (d)(1)–(3) · Economic Freedom — Requires FDA to define risk categories, assess foreign expedited systems, and propose within one year and finalize after comments manufacturing/CMC rules suitable for lower-risk phase 1 studies. Mechanism: FDA rules
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
Sec. 202(e)(1)–(3) · Economic Freedom — Defines higher-risk trials by genome modification, replication, irreversible biological effects, immune risk, prior clinical holds or unreasonable significant harm; lower-risk includes minimal-harm, exploratory/subtherapeutic or investigator-initiated trials. Mechanism: eligibility classification, not a new penalty
Sec. 202(a)–(e) · Government Power — Creates third-party phase 1 review, new risk classifications, pilot oversight and manufacturing rulemaking deadlines
SEC. 203. GLOBAL REGULATORY ALIGNMENT TO MODERNIZE CLINICAL DEVELOPMENT.
Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval
Sec. 203(b), new FDCA §704(i)(1)–(2) · Economic Freedom — Requires inspected clinical establishments to pre-certify GCP compliance; requires verification for covered biotechnology companies of concern and authorizes inspection-cost fees. Affected: site owners/operators/agents. Mechanism: FDA inspection, fees and approval decisions
Sec. 203(b), new FDCA §704(i)(1)–(2) · Privacy and Due Process — Imposes pre-certification and federal verification/inspection of specified clinical sites, with inspection cost fees. Mechanism: FDA inspection authority
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 302(b), amended FDCA §803(b)(3) · Economic Freedom — Requires bioresearch monitoring to seek reciprocal inspection reliance, reduced duplicate U.S. inspections and risk-based oversight. Mechanism: FDA regulatory collaboration
Sec. 203(b) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization
Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data
Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 203(c)(2) · Government Power — and may charge inspection fees
Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration
Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data
Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration
Sec. 203(c)(1)–(2) · Economic Freedom — Permits FDA to demand source data, audit trails, translated consent records and sample chains of custody for foreign phase 1–2 studies, and reject data for noncompliance. Affected: sponsors/investigators. Mechanism: FDA refusal to accept clinical data
Sec. 203(c)(1)(A)–(D), (c)(2) · Privacy and Due Process — Authorizes compelled foreign patient-level source data, audit trails, translated informed-consent records, specimen custody and other documentation; FDA may reject evidence if the sponsor refuses. Affected: foreign trial participants and sponsors. Mechanism: evidence exclusion at FDA
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
Sec. 203(c)(2) · Government Power — and may charge inspection fees
Sec. 203(c)(1)–(2) · Government Power — alongside long-term longitudinal genomic/clinical data integration
Sec. 203(a), amended FDCA §803(b)(2), (d)(1)–(2) · Economic Freedom — Adds international Good Clinical Practice recognition and FDA global coordination for foreign trials and real-world data. Mechanism: FDA inspection/approval
Sec. 203(d) · Economic Freedom — Requires FDA within 18 months to clarify consequences for delaying/denying inspections. Mechanism: guidance and existing inspection law
Sec. 203(a)–(d) · Government Power — Adds global GCP oversight, site certifications, fee authority, foreign trial data-documentation and rejection powers
SEC. 204. MINIMUM UNITED STATES REPRESENTATION IN CLINICAL TRIALS.
Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review
Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers
Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review
Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions
Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers
Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review
Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions
Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers
Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review
Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions
Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers
Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review
Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions
Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers
Sec. 204(a)–(b) · Economic Freedom — Requires U.S.-enrolled patients in specified pivotal studies and restricts approvals relying only on foreign clinical data, subject to statutory exceptions/waivers where domestic studies are unavailable, impracticable, or emergency conditions justify. Affected: drug and biologic sponsors. Mechanism: FDA marketing-application review
Sec. 204(b) · Privacy and Due Process — Gives FDA waiver/exception discretion for U.S. enrollment and foreign-data requirements, including public-health emergencies. Mechanism: FDA application decisions
Sec. 204(a)–(b) · Government Power — Adds FDA authority to enforce domestic-patient participation and grant defined waivers
SEC. 205. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
Sec. 205, new FDCA §1014A(a)(6)–(8) · Individual Rights — Requires patient/provider engagement and allows rare-disease sponsors consultation and escalation of review questions. Mechanism: FDA Hub administrative process
Sec. 205, new FDCA §1014A(a)–(c) · Economic Freedom — Creates rare-disease FDA Hub functions, reviewer consistency, technical assistance, sponsor consultations, grants/agreements and public-private manufacturing/clinical-center partnerships. Mechanism: FDA program and awards
Sec. 205, new §1014A(e)(1)(A)–(C) · Economic Freedom — Directs transfers of $5m/$10m/$15m from specified existing accounts to the Hub in each FY2027–2031, and requires presidential budget specification. Mechanism: federal fiscal administration, not three new stand-alone appropriations
Sec. 205, new FDCA §1014A(a)–(f) · Government Power — Establishes an FDA Rare Disease Innovation Hub, contracts/grants and partnerships, a public report due in nine months, FY2027–2031 transfers and incorporated definitions
SEC. 301. RESOLVING CLINICAL HOLDS AND IMPROVING CLINICAL TRIAL EFFICIENCY.
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)(6)–(7) · Privacy and Due Process — Requires clarification of confidential-information redaction and procedures for publishing FDA complete response letters and investigational/premarket application materials, including possible automation and pilot disclosure. Affected: applicants and public. Mechanism: FDA disclosure procedures subject to existing confidentiality law
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(a)(1)–(8) · Individual Rights — Directs FDA to address common clinical holds and approval delays, potentially improving participant access; creates agency duties rather than an individual right to an experimental drug. Mechanism: existing FDA IND/device oversight
Sec. 301(a)(1)–(8) · Economic Freedom — Requires FDA root-cause analysis of clinical holds, sponsor/IRB/CRO communication, process guidance, advisory use, staff expertise, response-letter redaction and startup navigation. Mechanism: FDA administrative practices, not automatic trial approval
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
Sec. 301(b) · Economic Freedom — Authorizes $500 million annually FY2027–2031 for process improvements, available until expended; not automatically appropriated
Sec. 301(a)–(b) · Government Power — Expands FDA clinical-hold process duties and authorizes $500 million per FY2027–2031
SEC. 302. MUTUAL RECOGNITION OF GMP STANDARDS.
Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law
Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination
Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law
Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination
Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law
Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law
Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination
Sec. 302(a), amended FDCA §809(a) · Economic Freedom — Broadens reliance on qualifying foreign government GMP inspections and related medical-product inspection recognition. Affected: manufacturers. Mechanism: FDA inspection law
Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination
Sec. 302(b), amended FDCA §803(b)(3) · Economic Freedom — Requires bioresearch monitoring to seek reciprocal inspection reliance, reduced duplicate U.S. inspections and risk-based oversight. Mechanism: FDA regulatory collaboration
Sec. 302(a)–(b) · Government Power — Expands foreign inspection recognition and international bioresearch monitoring coordination
SEC. 303. PATHWAY FOR COMPETITIVE GENERIC THERAPIES.
Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval
Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps
Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval
Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps
Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval
Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps
Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval
Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps
Sec. 303(a)–(c) · Economic Freedom — Requires FDA to review the competitive-generic-therapy pathway within 12 months, report recommendations and begin implementing them within six months after submission, consulting stakeholders. Mechanism: FDA program implementation; no automatic product approval
Sec. 303(a)–(c) · Government Power — Requires FDA competitive-generic pathway study and implementation steps
SEC. 304. BIOSIMILAR BIOLOGICAL PRODUCTS.
Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(a)(4)–(6), amended PHSA §351(k)(4), amended PHSA §351(k)(6) · Property Rights — Revises biosimilar interchangeability and preserves qualifying unexpired first-interchangeable exclusivity during transition; affects biologic applicants and exclusivity holders. Mechanism: FDA biologics licensure
Sec. 304(a)(1)–(6) · Economic Freedom — Removes the separate statutory interchangeability distinction and deems biosimilars interchangeable after a 60-day transition, subject to preserved exclusivity; revises related statutory language. Mechanism: FDA biologics licensing and substitution law
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(b), amended FDCA §505B(m) · Economic Freedom — Adjusts pediatric-assessment treatment of biosimilars based on reference-product indications and available formulations. Mechanism: existing pediatric drug/biologics review
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
Sec. 304(c)(1)–(3), (d)(1)–(2) · Economic Freedom — Requires biosimilar/interchangeability guidance updates within 18 months and follow-up after comments; preserves biosimilarity licensing standard and FDA evidence authority. Mechanism: FDA guidance/licensure
Sec. 304(a)–(d) · Government Power — Revises statutory biosimilar interchangeability, transition, pediatric assessments and FDA guidance
SEC. 305. CERTIFICATION OF PATENT INFORMATION IN CERTAIN APPLICATIONS FOR BIOLOGICAL PRODUCTS.
Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified
Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope
Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review
Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements
Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications
Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified
Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope
Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review
Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements
Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications
Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified
Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope
Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review
Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements
Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications
Sec. 305, new PHSA §351(o)(1)(A)(i)–(iv), (B) · Property Rights — Requires specified biologic applications relying on covered third-party investigations to certify each covered patent as unfiled, expired, expiring on a stated date, or invalid/noninfringed, and to distinguish irrelevant method-of-use patents. Affected: applicants and patent holders. Mechanism: FDA application completeness and existing patent procedures; no new infringement damages specified
Sec. 305, new §351(o)(2)(A)–(B) · Property Rights — Limits certifications to defined covered investigations and patents, including third-party studies used without a right of reference. Mechanism: statutory application scope
Sec. 305, new §351(o)(1)–(2) · Economic Freedom — Adds patent certifications and method-of-use statements to qualifying biologics applications. Mechanism: FDA application review
Sec. 305, new §351(o)(1)(A)–(B) · Privacy and Due Process — Requires applicants to make formal patent-status and noninfringement assertions; their legal significance depends on incorporated biologics and patent procedures. Mechanism: FDA application requirements
Sec. 305, new §351(o)(1)–(2) · Government Power — Adds patent-information certification requirements to covered biologic applications
SEC. 306. GAO REPORT.
Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty
Sec. 306(1)–(5) · Government Power — Requires GAO report within three years
Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty
Sec. 306(1)–(5) · Government Power — Requires GAO report within three years
Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty
Sec. 306(1)–(5) · Government Power — Requires GAO report within three years
Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty
Sec. 306(1)–(5) · Government Power — Requires GAO report within three years
Sec. 306(1)–(5) · Privacy and Due Process — Requires GAO review within three years of FDA process reforms, user-fee pilots and rare-disease effects; no individual hearing or penalty
Sec. 306(1)–(5) · Government Power — Requires GAO report within three years
SEC. 307. DEFINITIONS.
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
Sec. 307(1)–(9) · Government Power — Incorporates definitions of clinical investigations, good clinical practice, lower-resource sites, medical products and related terms; limits interpretation rather than independently creating penalties
SEC. 401. FINDINGS AND PURPOSE.
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
Sec. 401 — consists of nonoperative findings/purpose and is not independently scored. Each item below identifies its affected parties and enforcement mechanism. Where a provision only directs an agency to study, issue guidance, or report, no new private penalty is created by that provision. Existing FDA approval, inspection, human-subject protections, Medicare payment, and federal award conditions apply where indicated
Sec. 401(a)–(b) · Government Power — Legislative findings/purpose only; no independently operative obligation
SEC. 402. ONCOLOGY CENTER OF EXCELLENCE.
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(a)–(b) · Economic Freedom — Establishes FDA Oncology Center of Excellence as an Intercenter Institute for oncology/hematology review, coordination and stakeholder engagement. Affected: oncology developers and providers. Mechanism: FDA administration
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
Sec. 402(c)(1)–(2) · Economic Freedom — Requires FY2027–2031 transfers of such sums as necessary from specified existing FDA, interagency and ARPA-H-related funds, plus presidential budget identification. Mechanism: agency fiscal transfers, not an unrestricted new appropriation
Sec. 402(a)–(c) · Government Power — Establishes the Oncology Center of Excellence and funding transfers for FY2027–2031
SEC. 403. LABELING REVISIONS FOR GENOMIC EXCLUSIONS IN ONCOLOGY DRUGS.
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law
Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law
Sec. 403(a), (b)(1)–(2) · Economic Freedom — Requires a genomic-exclusion labeling assessment program within 12 months, identification of eligible oncology drugs and evidence channels, standardized language, voluntary supplements and agency updates where supported. Mechanism: FDA labeling process
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(c) · Individual Rights — Establishes FDA review of whether genetic subgroups should be excluded from indications in approved oncology-drug labeling, potentially affecting treatment information and access. Affected: patients, prescribers and sponsors. Mechanism: FDA labeling review; no direct ban on patient treatment created by this section
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(c)–(f) · Economic Freedom — Prescribes evaluation of evidence, actionable genetic alterations, diagnostic availability, clinical significance and engagement with sponsors and patient groups; governs FDA labeling decisions. Mechanism: FDA existing labeling powers
Sec. 403(b)(2)(A), (c)–(f) · Privacy and Due Process — Uses clinical/genomic evidence and potential diagnostic tests for population-level label changes; no new independent mandate to publicly disclose individual patients’ genotypes. Mechanism: FDA evidence review and existing health-data protections
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law
Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law
Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(b)(2)(C), (h)(1)–(2) · Property Rights — Encourages voluntary sponsor labeling supplements and preserves existing drug approval status except authorized label updates; does not independently transfer patent rights. Mechanism: FDA labeling law
Sec. 403(h)(1)–(2), (i)(1)–(3) · Privacy and Due Process — Preserves other FDA labeling authority and existing approvals except label updates; defines actionable genetic alteration, targeted therapy and genomic exclusion. Mechanism: existing FDA procedures
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
Sec. 403(a)–(i) · Government Power — Establishes FDA labeling assessment, stakeholder and evidence-review procedures, congressional reporting and definitions, while preserving existing FDA powers
SEC. 501. ESTABLISHMENT OF THE AMERICAN FRONTIER BIOBANK.
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law
Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards
Sec. 501(a), new §404P(i) · Economic Freedom — Authorizes $500 million for FY2027 and each subsequent fiscal year, available until expended; no statutory end date. This is an authorization, not an automatic appropriation
Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law
Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight
Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law
Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation
Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy
Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance
Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset
Sec. 501(a), Sec. 404P(i) · Government Power — most other agency study, guidance and grant provisions create no new standalone criminal penalty. Appropriation authorizations are not assumed to have been funded. The five titles contain no general sunset; the FY2027–2031 limits on some authorities do not sunset the permanent Biobank authorization
Sec. 501(a), Sec. 404P(d)(5)–(10) · Government Power — notwithstanding explicit consent safeguards
Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator
Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law
Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator
Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law
Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator
Sec. 501(a), new §404P(b)(1)–(2) · Property Rights — Transfers existing All of Us program authorities, appropriations, personnel, data, specimens and infrastructure to the new federal Biobank; no compulsory private property taking is specified. Mechanism: NIH internal transition and existing award law
Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator
Sec. 501(a), new §404P(a)–(c) · Government Power — Creates the American Frontier Biobank under NIH, transfers All of Us authorities, budget, staff and infrastructure within six months, and creates an NIH-appointed Administrator
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards
Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law
Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight
Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law
Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards
Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(d)(1)–(2) · Privacy and Due Process — Authorizes collection/storage of biospecimens, longitudinal molecular/clinical data and electronic health records, with a target cohort of at least 3% of the population. Mechanism: NIH agreements and existing consent/privacy law
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards
Sec. 501(a), new §404P(d)(3)–(4) · Privacy and Due Process — Requires mutually agreed tribal participation and data-sharing agreements with private/nonprofit partners to recruit, enroll and obtain informed consent. Mechanism: consultation and contractual oversight
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(5)–(7) · Privacy and Due Process — Requires trial recruitment using Biobank data, sharing deidentified data with all registered researchers and incorporating NIH/VA datasets including All of Us and Million Veteran Program. Mechanism: NIH researcher registration, agreements and privacy law
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(1), new §404P(d)(4), new §404P(d)(11) · Economic Freedom — Requires nationwide corporate/nonprofit awards and data-sharing agreements and permits public/private financing to collect/analyze specimens and clinical data. Affected: research institutions and contractors. Mechanism: federal contracts and awards
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(d)(1)–(12) · Government Power — Establishes nationwide cohort recruitment, contracting, data-sharing, genomic research and AI-infrastructure duties; allows additional activities determined by its advisory board
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(e)(1)–(8) · Government Power — Creates a national advisory board with NIH, agency, research, healthcare, technology, industry and ethics representatives
Sec. 501(a), new §404P(d)(8)–(10), (f) · Privacy and Due Process — Authorizes integrated genomic/proteomic/metabolomic and health-record data, repeat sampling, continuous data integration, federated AI-ready systems and linked environmental/life-course data. Mechanism: NIH program controls; reidentification risk and specific access safeguards depend on implementation
Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy
Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy
Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance
Sec. 501(a), new PHSA §404P(d)(2)–(5), (g)(1)–(2) · Individual Rights — Directs recruitment of a representative cohort of at least 3% of the U.S. population, including a pediatric cohort and tribal consultation, with informed consent required for collection and use. Affected: prospective participants and legally authorized representatives. Mechanism: NIH award/oversight and incorporated human-subject law; no mandatory individual enrollment
Sec. 501(a), new §404P(g)(1)(A)–(B), (g)(2) · Privacy and Due Process — Requires informed consent or authorized-representative permission and at least existing federal/state privacy protections for biospecimens and associated clinical/demographic data. Mechanism: incorporated human-subject/privacy laws and NIH oversight; no independent new statutory damages remedy
Sec. 501(a), new §404P(f)–(g) · Government Power — Permits multimodal data linkage and requires consent and privacy compliance
Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset
Sec. 501(a), new §404P(i) · Economic Freedom — Authorizes $500 million for FY2027 and each subsequent fiscal year, available until expended; no statutory end date. This is an authorization, not an automatic appropriation
Sec. 501(a), new §404P(h)–(i) · Government Power — Requires annual congressional notification beginning one year after enactment and authorizes $500 million in FY2027 and every later fiscal year, without an express sunset
Sec. 501(b) · Economic Freedom — Requires NIH within 180 days to submit a five-fiscal-year scientific, infrastructure, partnership-financing and budget roadmap. Mechanism: congressional oversight
Sec. 501(b) · Government Power — Requires a five-year implementation and financing roadmap within 180 days
Findings source: bill-scores-v2-batch33-findings-2026-11-14.md. Highlights come only from that file; no finding, score, or provision was invented for this page.
What you can do
Contact your U.S. Representative and Senators about this bill.
Find your Representative Contact your Senators
Spot an error on this page? Report it.